IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Earnings for IGM Biosciences, Inc. (IGMS)
Earnings in 2023 (TTM): $-245,738,000
According to IGM Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-245,738,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of IGM Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-245,738,000 | $-246,416,000 |
| 2022 | $-221,102,000 | $-214,248,000 |
| 2021 | $-165,164,000 | $-160,680,000 |
| 2020 | $-81,355,000 | $-80,330,000 |
| 2019 | $-43,133,000 | $-42,536,000 |
| 2018 | $-22,711,000 | $-22,711,000 |
| 2017 | $-11,054,000 | $-11,054,000 |